P/E at 34.7 vs Industry's 31.5: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Above Industry Average

Sun Pharmaceutical Industries Ltd trades at a P/E of 34.71, which is approximately 10% higher than the Pharmaceuticals & Biotechnology industry average of 31.53. This premium suggests that investors are willing to pay more for the stock relative to its peers, potentially reflecting expectations of superior earnings growth or a perception of higher quality within the company’s fundamentals. However, such a premium also raises questions about valuation sustainability, especially in a sector where competitive pressures and regulatory risks are prevalent. The current P/E multiple places the stock in a valuation bracket that demands consistent performance to justify the premium — previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating? The four-parameter analysis factors in this valuation premium alongside other metrics.

Performance Across Timeframes: Mixed Momentum

Examining the stock’s returns reveals a complex performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a modest gain of 0.22%, outperforming the Sensex’s decline of 4.09% during the same period. This relative resilience is further underscored by the stock’s three-month return of 1.86%, which contrasts sharply with the Sensex’s 12.39% loss. The year-to-date performance of 2.91% also outpaces the broader market’s negative 12.20%, indicating that the stock has been a relative safe haven within the sector.

Shorter-term returns, however, show some volatility. The one-week performance is down 0.50%, while the one-month gain is a modest 0.34%. The stock’s day change of 0.97% slightly trails the Sensex’s 1.02% gain, reflecting a cautious trading environment. This divergence between short-term softness and medium-term strength raises the question of whether recent weakness is a temporary correction or indicative of emerging headwinds — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Signs of a Recovery Within a Larger Trend

The technical picture for Sun Pharmaceutical Industries Ltd is characterised by its position relative to key moving averages. The stock currently trades above its 5-day, 50-day, 100-day, and 200-day moving averages, signalling short to long-term support levels have been breached on the upside. However, it remains below the 20-day moving average, indicating some recent resistance and a potential pause in momentum.

This configuration suggests a recovery phase within a broader trend, where the stock has bounced back from recent lows but has yet to fully regain short-term momentum. The fact that it is close to its 52-week high — just 4.18% away from Rs 1850.95 — adds to the narrative of a stock attempting to consolidate gains. The 2-day gain following a two-day consecutive fall further supports this interpretation — is this a one-quarter anomaly or the start of a structural revenue problem? — while operating margins simultaneously hit their lowest recorded level, suggesting the pressure is not confined to the top line alone.

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently, with 34 stocks having declared their earnings. Of these, 16 reported positive outcomes, 9 were flat, and 9 posted negative results. This distribution highlights the sector’s uneven performance landscape, where Sun Pharmaceutical Industries Ltd appears to be navigating a challenging environment with relative stability.

The stock’s outperformance relative to the Sensex across multiple timeframes, including a 3-year return of 81.93% versus the Sensex’s 30.07%, and a 5-year return of 206.54% compared to the Sensex’s 54.47%, underscores its long-term resilience. However, the 10-year return of 109.05% trails the Sensex’s 195.32%, reflecting periods of underperformance in the more distant past.

Rating Context: Previously Hold, Now Reassessed

On 23 Feb 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from Hold, reflecting a reassessment of its fundamentals and market position. The current Mojo Score stands at 72.0, indicating a positive outlook based on the four-parameter analysis that includes valuation, performance, technicals, and sector context. This rating shift aligns with the stock’s relative outperformance over the past year and its technical recovery, but it also takes into account the premium valuation and recent short-term volatility — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Complex Picture of Valuation and Momentum

The data for Sun Pharmaceutical Industries Ltd paints a nuanced picture. The stock commands a valuation premium over its industry peers, which is supported by relative outperformance in medium to long-term timeframes. However, short-term momentum shows signs of hesitation, reflected in the moving average configuration and recent price action. The sector’s mixed results further complicate the outlook, underscoring the importance of monitoring earnings trends and technical signals closely.

Investors analysing this large-cap pharmaceutical stock must weigh the premium valuation against the demonstrated resilience and recent technical recovery. The reassessment of the rating from Hold to a more positive stance by MarketsMOJO reflects this balance of factors — what is the current rating for Sun Pharmaceutical Industries Ltd?

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today